About Leap Therapeutics, Inc. - Common Stock (LPTX)
Leap Therapeutics Inc. is a biopharmaceutical company focused on developing innovative therapies to improve the lives of patients with cancer and other diseases. The company's research primarily centers on advancing novel antibody-based treatments and biologics that target specific pathways involved in tumor growth and immune response. By leveraging cutting-edge scientific advancements, Leap Therapeutics aims to bring new hope to patients through its clinical programs, which explore potential solutions for previously unmet medical needs. The company collaborates with academic institutions and industry partners to accelerate the development of its therapeutic candidates. Read More
Roadzen Inc. (NASDAQ: RDZN), a global AI leader in insurance and mobility, announced the completion of a $7 million India financing led by Team India, Quant AMC, Valentis Advisors, and Prime Securities Group , valuing its India unit at $91 million and implying a $2 per share parent valuation — nearly double its current market price .
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
October 6, 2025 – In a seismic shift that reverberated across both traditional financial markets and the burgeoning crypto ecosystem, Leap Therapeutics (NASDAQ: LPTX), a clinical-stage biotechnology company, today announced a landmark private placement deal. The $58.88 million to $58.9 million investment, spearheaded by prominent crypto investors Winklevoss Capital, is set to not only bolster [...]
Boston, MA – October 3, 2025 – Leap Therapeutics, Inc. (NASDAQ: LPTX) experienced a sharp downturn in its stock performance today, with shares falling by over 20% in intraday trading. This significant decline marks a notable correction for the biotechnology company, which had seen its stock surge dramatically in the preceding days,
Health In Tech Inc. (NASDAQ: HIT), OSR Holdings Inc. (NASDAQ: OSRH), Theratechnologies Inc. (NASDAQ: THTX), and Leap Therapeutics Inc. (NASDAQ: LPTX) continue to push boundaries in healthcare through breakthroughs in insurtech, virtual access, immunotherapy, biologics, and precision oncology.
Leap Therapeutics' Phase 2 trial data show sirexatamab boosts response rates and survival in MSS colorectal cancer, with ongoing business development plans.
